公开(公告)号：US20230192643A1

公开(公告)日：2023-06-22

申请号：US17878753

申请日：2022-08-01

申请人： C4 Therapeutics, Inc.

发明人： Roger Norcross ,  Adrian Britschgi ,  Fabian Dey ,  Annick Goergler ,  Eric Andre Kusznir ,  Moreno Attilio Wichert

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D519/00

CPC分类号： C07D401/04 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D519/00

摘要： The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

公开(公告)号：US20200207733A1

公开(公告)日：2020-07-02

申请号：US16809345

申请日：2020-03-04

申请人： C4 Therapeutics, Inc.

发明人： Roger Norcross ,  Adrian Britschgi ,  Fabian Dey ,  Annick Goergler ,  Eric Andre Kusznir ,  Moreno Attilio Wichert

IPC分类号： C07D401/04 ,  C07D413/14 ,  C07D471/04 ,  C07D401/14 ,  C07D519/00

摘要： The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.

公开(公告)号：US12091397B2

公开(公告)日：2024-09-17

申请号：US17878753

申请日：2022-08-01

申请人： C4 Therapeutics, Inc.

发明人： Roger Norcross ,  Adrian Britschgi ,  Fabian Dey ,  Annick Goergler ,  Eric Andre Kusznir ,  Moreno Attilio Wichert

IPC分类号： C07D401/04 ,  A61K31/4375 ,  A61K31/4704 ,  A61K47/55 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/14 ,  C07D519/00

CPC分类号： C07D401/04 ,  A61K31/4375 ,  A61K31/4704 ,  A61K47/55 ,  A61P35/00 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  C07D495/14 ,  C07D519/00

摘要： The present invention provides dihydroquinolinone compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.